Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.

× No keyword cloud information.

11 in total

Review 1. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors: Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal: Drug Saf Date: 2013-07 Impact factor: 5.606

2. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.

Authors: Tsukasa Yoshida; Kazuhiko Yamada; Koichi Azuma; Akihiko Kawahara; Hideyuki Abe; Satoshi Hattori; Fumie Yamashita; Yoshiaki Zaizen; Masayoshi Kage; Tomoaki Hoshino
Journal: Med Oncol Date: 2012-12-22 Impact factor: 3.064

3. Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib.

Authors: Tatsuya Nagano; Yoshikazu Kotani; Kazuyuki Kobayashi; Masahiro Katsurada; Yukihisa Hatakeyama; Suya Hori; Daisuke Tamura; Daisuke Kasai; Yasuhiro Funada; Yoshihiro Nishimura
Journal: Case Rep Pulmonol Date: 2011-12-25

4. Treatment with gefitinib after erlotinib-induced liver injury: a case report.

Authors: Katsumi Nakatomi; Yoichi Nakamura; Iida Tetsuya; Shigeru Kohno
Journal: J Med Case Rep Date: 2011-12-21

5. Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases.

Authors: Yukihiro Yano; Yoshinobu Namba; Masahide Mori; Yukie Nakazawa; Ayumi Nashi; Shinichi Kagami; Manabu Niinaka; Tsutomu Yoneda; Hiromi Kimura; Toshihiko Yamaguchi; Soichiro Yokota
Journal: Lung Cancer Int Date: 2012-11-08

Review 6. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.

Authors: Yosuke Togashi; Hidetoshi Hayashi; Kazuhiko Nakagawa; Kazuto Nishio
Journal: Drug Des Devel Ther Date: 2014-07-31 Impact factor: 4.162

7. Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors

Authors: Qi-Qi Zhu; Chun Wang; Yue-Yun Chen; Zhen-Yu Ding
Journal: Asian Pac J Cancer Prev Date: 2018-08-24

8. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.

Authors: Tomohiro Suzumura; Tatsuo Kimura; Shinzoh Kudoh; Kanako Umekawa; Misato Nagata; Kuniomi Matsuura; Hidenori Tanaka; Shigeki Mitsuoka; Naruo Yoshimura; Yukimi Kira; Toshiyuki Nakai; Kazuto Hirata
Journal: BMC Cancer Date: 2012-12-04 Impact factor: 4.430

9. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis.

Authors: Yuanyuan Liu; Yu Zhang; Gangling Feng; Qiang Niu; Shangzhi Xu; Yizhong Yan; Shugang Li; Mingxia Jing
Journal: Exp Ther Med Date: 2017-09-01 Impact factor: 2.447

10. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.

Authors: Zhe Wang; Xiaoyu Wang; Zhen Wang; Yuyi Feng; Yaqin Jia; Lili Jiang; Yangliu Xia; Jun Cao; Yong Liu
Journal: JAMA Netw Open Date: 2021-07-01